{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T00:51:10Z","timestamp":1794271870631,"version":"4.9.0"},"reference-count":21,"publisher":"Bioscientifica","issue":"6","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":241,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82072951"],"award-info":[{"award-number":["82072951"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"crossref","award":["19411966600"],"award-info":[{"award-number":["19411966600"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100017633","name":"Shanghai Anti-Cancer Association","doi-asserted-by":"crossref","award":["SACA-AX106"],"award-info":[{"award-number":["SACA-AX106"]}],"id":[{"id":"10.13039\/100017633","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Shanghai Shen-kang Hospital Development Center","award":["SHDC2024CRI030"],"award-info":[{"award-number":["SHDC2024CRI030"]}]}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Poorly differentiated thyroid cancer (PDTC) and anaplastic thyroid cancer (ATC) are both rare and aggressive thyroid cancers. Advances in targeted therapy and immunotherapy have changed treatment strategies and improved prognosis in these patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This single-center cohort study included patients diagnosed with locally advanced or metastatic PDTC\/ATC at Fudan University Shanghai Cancer Center (FUSCC) between 2019 and 2023. Patients were either enrolled in clinical trials or received treatment based on clinical guidelines and expert consensus. Gene testing was conducted using next-generation sequencing of clinical samples.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>95 patients were analyzed (PDTC = 34, ATC = 61). Median overall survival (OS) was 19.7 months for PDTC and 9.5 months for ATC (P = 0.478). Among 82 patients who underwent gene testing, the most frequent gene alterations in PDTC were BRAF (50.0%), TERT promoter (39.3%), and TP53 (25.0%) mutations; in ATC, they were TERT promoter (55.6%), BRAF (42.6%), and TP53 (25.9%) mutations. Compared with ATC patients, PDTC patients were more likely to receive best supportive care and less likely to be enrolled in clinical trials or treated with PD-1 inhibitors. The 1-year OS rates for PDTC\/ATC patients receiving neoadjuvant therapy + surgery, systemic treatment, and supportive care only were 83.3, 51.2, and 5.7%, respectively (P &amp;lt; 0.001). After adjusting for covariates, neoadjuvant therapy + surgery (hazard ratio = 0.216, 95% confidence interval: 0.647\u20130.718, P = 0.012) was an independent predictor of superior OS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Despite the generally poor prognosis, aggressive treatment, particularly neoadjuvant therapy, has been shown to improve survival. Personalized treatment is crucial for optimizing treatment strategies for PDTC\/ATC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1530\/etj-24-0371","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T13:37:41Z","timestamp":1760708261000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-17","source":"Crossref","is-referenced-by-count":4,"title":["Personalized treatment of 95 poorly differentiated thyroid cancer\/anaplastic thyroid cancer in 2019\u20132023"],"prefix":"10.1530","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7623-5744","authenticated-orcid":true,"given":"Nai-Si","family":"Huang","sequence":"first","affiliation":[{"name":"1"},{"name":"2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Ying","family":"Chen","sequence":"additional","affiliation":[{"name":"1"},{"name":"2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Jun","family":"Wei","sequence":"additional","affiliation":[{"name":"1"},{"name":"2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Qian","family":"Hu","sequence":"additional","affiliation":[{"name":"1"},{"name":"2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Jun","family":"Wang","sequence":"additional","affiliation":[{"name":"1"},{"name":"2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan-Lin","family":"Liu","sequence":"additional","affiliation":[{"name":"1"},{"name":"2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Guan","sequence":"additional","affiliation":[{"name":"1"},{"name":"2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuan-Qi","family":"Sun","sequence":"additional","affiliation":[{"name":"1"},{"name":"2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3830-7257","authenticated-orcid":true,"given":"Yu-Long","family":"Wang","sequence":"additional","affiliation":[{"name":"1"},{"name":"2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Xiang","sequence":"additional","affiliation":[{"name":"1"},{"name":"2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-Hai","family":"Ji","sequence":"additional","affiliation":[{"name":"1"},{"name":"2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Mei","family":"Ji","sequence":"additional","affiliation":[{"name":"2"},{"name":"3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1735-0473","authenticated-orcid":true,"given":"Yu","family":"Wang","sequence":"additional","affiliation":[{"name":"1"},{"name":"2"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"key":"2026070714024135300_bib1","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1089\/thy.2020.0944","article-title":"2021 American Thyroid Association Guidelines for Management of patients with anaplastic thyroid cancer","volume":"31","author":"Bible","year":"2021","journal-title":"Thyroid"},{"key":"2026070714024135300_bib2","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1210\/jc.2013-3842","article-title":"Outcomes in patients with poorly differentiated thyroid carcinoma","volume":"99","author":"Ibrahimpasic","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070714024135300_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2024.1345203","article-title":"Tyrosine kinase inhibitors in patients with advanced anaplastic thyroid cancer: an effective analysis based on real-world retrospective studies","volume":"15","author":"Kuang","year":"2024","journal-title":"Front Endocrinol"},{"key":"2026070714024135300_bib4","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12902-024-01555-y","article-title":"First effectiveness data of lenvatinib and pembrolizumab as first-line therapy in advanced anaplastic thyroid cancer: a retrospective cohort study","volume":"24","author":"Soll","year":"2024","journal-title":"BMC Endocr Disord"},{"key":"2026070714024135300_bib5","doi-asserted-by":"crossref","first-page":"e60","DOI":"10.1016\/j.clon.2022.10.017","article-title":"Dabrafenib and trametinib therapy for advanced anaplastic thyroid cancer \u2013 real-world outcomes from UK centres","volume":"35","author":"Lorimer","year":"2023","journal-title":"Clin Oncol"},{"key":"2026070714024135300_bib6","article-title":"Comparative study between poorly differentiated thyroid cancer and anaplastic thyroid cancer: real-world pathological distribution, death attribution, and prognostic factor estimation","volume":"15","author":"Zhang","year":"2024","journal-title":"Front Endocrinol"},{"key":"2026070714024135300_bib7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.2017.73.6785","article-title":"Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600\u2013mutant anaplastic thyroid cancer","volume":"36","author":"Subbiah","year":"2017","journal-title":"J Clin Oncol"},{"key":"2026070714024135300_bib8","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1056\/NEJMoa2005651","article-title":"Efficacy of selpercatinib in RET-altered thyroid cancers","volume":"383","author":"Wirth","year":"2020","journal-title":"New Engl J Med"},{"key":"2026070714024135300_bib9","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1089\/thy.2020.0322","article-title":"Combination of lenvatinib and pembrolizumab is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma","volume":"31","author":"Dierks","year":"2021","journal-title":"Thyroid"},{"key":"2026070714024135300_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12020-024-03845-w","article-title":"Efficacy and safety of BRAF\/MEK inhibitors in BRAFV600E-mutated anaplastic thyroid cancer: a systematic review and meta-analysis","volume":"86","author":"Priantti","year":"2024","journal-title":"Endocrine"},{"key":"2026070714024135300_bib11","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1089\/thy.2023.0573","article-title":"Checkpoint inhibition in addition to dabrafenib\/trametinib for BRAFV600E-Mutated anaplastic thyroid carcinoma","volume":"34","author":"Hamidi","year":"2024","journal-title":"Thyroid"},{"key":"2026070714024135300_bib12","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ejca.2022.06.044","article-title":"Phase II study of the efficacy and safety of lenvatinib for anaplastic thyroid cancer (HOPE)","volume":"173","author":"Higashiyama","year":"2022","journal-title":"Eur J Cancer"},{"key":"2026070714024135300_bib13","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1200\/JCO.20.03093","article-title":"Open-label, single-arm, multicenter, phase II trial of lenvatinib for the treatment of patients with anaplastic thyroid cancer","volume":"39","author":"Wirth","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026070714024135300_bib14","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.173712","article-title":"A distinct tumor microenvironment makes anaplastic thyroid cancer more lethal but immunotherapy sensitive than papillary thyroid cancer","volume":"9","author":"Han","year":"2024","journal-title":"JCI Insight"},{"key":"2026070714024135300_bib15","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1210\/clinem\/dgae271","article-title":"Genomic landscape and clinical features of advanced thyroid carcinoma: A National Database Study in Japan","volume":"109","author":"Toda","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070714024135300_bib16","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1200\/JCO.2014.55.5094","article-title":"BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence","volume":"32","author":"Xing","year":"2014","journal-title":"J Clin Oncol"},{"key":"2026070714024135300_bib17","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1001\/jamaoncol.2016.3288","article-title":"Mortality risk stratification by combining BRAF V600E and TERT promoter mutations in papillary thyroid cancer: genetic duet of BRAF and TERT promoter mutations in thyroid cancer mortality","volume":"3","author":"Liu","year":"2016","journal-title":"JAMA Oncol"},{"key":"2026070714024135300_bib18","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1158\/1078-0432.CCR-23-0278","article-title":"Additional oncogenic alterations in RAS-driven differentiated thyroid cancers associate with worse clinicopathologic outcomes","volume":"29","author":"Bikas","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2026070714024135300_bib19","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1007\/s00268-022-06739-y","article-title":"Impact of local control on clinical course in stage IVC anaplastic thyroid carcinoma","volume":"46","author":"Yamazaki","year":"2022","journal-title":"World J Surg"},{"key":"2026070714024135300_bib20","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1089\/thy.2019.0133","article-title":"Complete surgical resection following neoadjuvant dabrafenib plus trametinib inBRAFV600E-mutated anaplastic thyroid carcinoma","volume":"29","author":"Wang","year":"2019","journal-title":"Thyroid"},{"key":"2026070714024135300_bib21","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1089\/thy.2022.0504","article-title":"Surgery after BRAF-directed therapy is associated with improved survival in BRAFV600E mutant anaplastic thyroid cancer: a single-center retrospective cohort study","volume":"33","author":"Zhao","year":"2023","journal-title":"Thyroid"}],"container-title":["European Thyroid Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/etj.bioscientifica.com\/view\/journals\/etj\/14\/6\/ETJ-24-0371.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/etj.bioscientifica.com\/downloadpdf\/journals\/etj\/14\/6\/ETJ-24-0371.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article-pdf\/doi\/10.1530\/ETJ-24-0371\/506820\/etj-24-0371.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article-pdf\/doi\/10.1530\/ETJ-24-0371\/506820\/etj-24-0371.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T18:02:52Z","timestamp":1783447372000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article\/14\/6\/e240371\/75702\/Personalized-treatment-of-95-poorly-differentiated"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1530\/etj-24-0371","relation":{},"ISSN":["2235-0802","2235-0640"],"issn-type":[{"value":"2235-0802","type":"electronic"},{"value":"2235-0640","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,17]]},"article-number":"e240371"}}